Jeremy Hugh

Jeremy Hugh

Auto-generated profile, based on publicly available information

Jeremy Hugh

Department of Dermatology, Stony Brook University Hospital, Stony Brook, NY, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in JMIR Dermatology
Verified
Journal Article
Open access
SSSamantha S. Sattler
Samantha S. Sattler
NCNITIN CHETLA
NITIN CHETLA
MCMatthew Chen
Matthew Chen
THTamer Rajai Hage
Tamer Rajai Hage
JCJoseph Chang
Joseph Chang
JHJeremy Hugh
Jeremy Hugh
ChatGPT is increasingly used in healthcare. Fields like dermatology and radiology could benefit from ChatGPT’s ability to help clinicians diagnose skin lesions. This study evaluates the accuracy of ChatGPT in diagnosing melanoma. Our analysis indicates that ChatGPT cannot be used reliably to diagnose melanoma, and further improvements are needed to reach this capability.

7 December 2015 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
ABAgnes Balla
Agnes Balla
JPJoseph Pierson
Joseph Pierson
JHJeremy Hugh
Jeremy Hugh
CWChristina Wojewoda
Christina Wojewoda
PGPamela Gibson
Pamela Gibson
LGLaura Greene
Laura Greene

20 July 2023 in JMIR Dermatology
Verified
Journal Article
Open access
SZSophia Zita
Sophia Zita
LBLindsey Broussard
Lindsey Broussard
JHJeremy Hugh
Jeremy Hugh
SNSabrina Newman
Sabrina Newman
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, life-threatening reaction to a culprit drug that frequently involves end-organ damage. Corticosteroids are the first-line treatment for DRESS syndrome; however, corticosteroids may be contraindicated in certain patient populations. There are currently only 54 cases detailing the use of cyclosporine for the treatment of DRESS syndrome reported in the literature. Objective: The aim of this case series was to examine the treatment of DRESS syndrome with cyclosporine in a large patient cohort by aggregating time to symptom resolution, recurrence rate, and treatment dose and duration. Methods: This study was a retrospective cohort study. Patients diagnosed with DRESS syndrome by a board-certified dermatologist and treated at the University of Colorado Hospital from 2015 to 2019 were included. Results: Our inclusion criterion was met by 19 occurrences of DRESS syndrome. With a short course of cyclosporine, 17 of 19 patients in our cohort (89%) had resolution of symptoms (mean treatment length of 5.26 days). DRESS syndrome’s relapse after treatment with cyclosporine occurred in 3 of 19 (16%) occurrences of the cohort. Conclusions: Our study supports the use of cyclosporine in the treatment of DRESS syndrome, particularly in patients who are unable to sustain prolonged immunosuppression. Further research is necessary to compare the efficacy of cyclosporine to the current standard of care in a larger study population and investigate long-term outcomes.

24 August 2021 in Journal of the Dermatology Nurses' Association
Verified
Journal Article
Closed access
MLMelissa R. Laughter
Melissa R. Laughter
MMMayra B. C. Maymone
Mayra B. C. Maymone
CPColby L. Presley
Colby L. Presley
SNSarah Nodine
Sarah Nodine
MSMindy D. Szeto
Mindy D. Szeto
CDCory A. Dunnick
Cory A. Dunnick
Numbers and roles of advanced practice providers (APPs) in dermatology have expanded tremendously over the last five decades. Although the imbalance between demand for dermatology services and available dermatologists may contribute to this increase, little research has been done to examine the evolving roles of APPs and ongoing trends as represented by scientific publications. To analyze publication trends, key topics, and perceptions related to APPs, the PubMed database was searched for all articles related to APPs in dermatology published from 1973 to 2018. The number of publications, citation counts, and favorability toward APPs were assessed and scored by two independent evaluators. Increased prevalence of APPs in dermatology mirrors a substantial increase in the total number of APP-related publications, whereas the proportion of publications showing positive perceptions of APPs was found to decrease over time. Top-cited articles focused on dermatology workforce shortages, roles of APPs, and comparisons of efficacy among providers. We hope this study will offer insight to all healthcare providers with considerations regarding the evolving roles of APPs in dermatology.

24 July 2022 in JMIR Preprints
Verified
Preprint
Open access
SZSophia Zita
Sophia Zita
LBLindsey Broussard
Lindsey Broussard
JHJeremy Hugh
Jeremy Hugh
SNSabrina Newman
Sabrina Newman
BACKGROUND Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, life-threatening reaction to a culprit drug that frequently involves end-organ damage. Corticosteroids are the first-line treatment for DRESS syndrome; however, corticosteroids may be contraindicated in certain patient populations. There are currently only 54 cases detailing the use of cyclosporine for the treatment of DRESS syndrome reported in the literature. OBJECTIVE The aim of this case series was to examine the treatment of DRESS syndrome with cyclosporine in a large patient cohort by aggregating time to symptom resolution, recurrence rate, and treatment dose and duration. METHODS This study was a retrospective cohort study. Patients diagnosed with DRESS syndrome by a board-certified dermatologist and treated at the University of Colorado Hospital from 2015 to 2019 were included. RESULTS Our inclusion criterion was met by 19 occurrences of DRESS syndrome. With a short course of cyclosporine, 17 of 19 patients in our cohort (89%) had resolution of symptoms (mean treatment length of 5.26 days). DRESS syndrome’s relapse after treatment with cyclosporine occurred in 3 of 19 (16%) occurrences of the cohort. CONCLUSIONS Our study supports the use of cyclosporine in the treatment of DRESS syndrome, particularly in patients who are unable to sustain prolonged immunosuppression. Further research is necessary to compare the efficacy of cyclosporine to the current standard of care in a larger study population and investigate long-term outcomes. CLINICALTRIAL